The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin
Open accessAbstract
Expression of hepcidin, the key hormone governing iron transport, is reduced by anemia in a manner which appears dependent on increased bone marrow activity. The temporal associations between plasma hepcidin and other iron parameters were examined in healthy humans after erythropoietin administration and venesection. Profound hepcidin suppression appeared abruptly 24 hours after subcutaneous erythropoietin (P=0.003), and was near maximal at onset, with peak (mid-afternoon) levels reduced by 73.2%, gradually recovering over the following two weeks. Minor changes in circulating iron, soluble transferrin receptor and growth differentiation factor-15 were observed after the reduction in hepcidin. Similar but more gradual changes in these parameters were observed after reducing hematocrit by removal of 250 mL blood. These human studies confirm the importance of a rapidly responsive marrow-hepcidin axis in regulating iron supply in vivo, and suggest that this axis is regulated by factors other than circulating iron, soluble transferrin receptor or growth differentiation factor-15.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“studies in humans receiving recombinant EPO have not yet shown a significant inverse relationship between serum hepcidin and GDF15 levels”
From Regulation of erythropoiesis by hypoxia-inducible factors (2013) · cites this paper as [222]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417
Nicolas, G., Chauvet, C., Viatte, L., Danan, J. L., Bigard, X., Devaux, I., Beaumont, C., Kahn, A., & Vaulont, S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215686 · Cited by 1,214
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin
Tanno, T., Bhanu, N. V., Oneal, P. A., Goh, S.-H., Staker, P., Lee, Y. T., Moroney, J. W., Reed, C. H., Luban, N. L., Wang, R.-H., et al. (2007) · Nature Medicine · doi:10.1038/nm1629 · Cited by 854
Immunoassay for human serum hepcidin
Ganz, T., Olbina, G., Girelli, D., Nemeth, E., & Westerman, M. (2008) · Blood · doi:10.1182/blood-2008-02-139915 · Cited by 688
Bridle, K. R., Frazer, D. M., Wilkins, S. J., Dixon, J. L., Purdie, D. M., Crawford, D. H., Subramaniam, V. N., Powell, L. W., Anderson, G. J., & Ramm, G. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12602-5 · Cited by 620
Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS
Kemna, E., Pickkers, P., Nemeth, E., van der Hoeven, H., & Swinkels, D. (2005) · Blood · doi:10.1182/blood-2005-03-1159 · Cited by 498
Suppression of hepcidin during anemia requires erythropoietic activity
Pak, M., Lopez, M. A., Gabayan, V., Ganz, T., & Rivera, S. (2006) · Blood · doi:10.1182/blood-2006-06-028787 · Cited by 472
Hepcidin in iron overload disorders
Papanikolaou, G., Tzilianos, M., Christakis, J. I., Bogdanos, D., Tsimirika, K., MacFarlane, J., Goldberg, Y. P., Sakellaropoulos, N., Ganz, T., & Nemeth, E. (2005) · Blood · doi:10.1182/blood-2004-12-4844 · Cited by 445
Hepcidin is decreased in TFR2 hemochromatosis
Nemeth, E., Roetto, A., Garozzo, G., Ganz, T., & Camaschella, C. (2004) · Blood · doi:10.1182/blood-2004-08-3042 · Cited by 399
Molecular control of iron transport
Ganz, T. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070802 · Cited by 353
Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease
Ashby, D. R., Gale, D. P., Busbridge, M., Murphy, K. G., Duncan, N. D., Cairns, T. D. H., Taube, D. H., Bloom, S. R., Tam, F. W. K., Chapman, R., et al. (2009) · Kidney International · doi:10.1038/ki.2009.21 · Cited by 313
Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis
Vokurka, M., Krijt, J., Šulc, K., & Nečas, E. (2006) · Physiological Research · doi:10.33549/physiolres.930841 · Cited by 263
Détivaud, L., Nemeth, E., Boudjéma, K., Turlin, B., Troadec, M., Leroyer, P., Ropert, M., Jacquelinet, S., Courselaud, B., Ganz, T., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4855 · Cited by 191
Kattamis, A., Papassotiriou, I., Palaiologou, D., Apostolakou, F., Galani, A., Ladis, V., Sakellaropoulos, N., & Papanikolaou, G. (2006) · PubMed · Cited by 156
Erythropoietin is both a mitogen and a survival factor
Spivak, J., Pham, T. D., Isaacs, M. A., & Hankins, W. D. (1991) · Blood · doi:10.1182/blood.v77.6.1228.1228 · Cited by 153
FERROKINETICS IN NORMAL PERSONS AND IN PATIENTS HAVING VARIOUS ERYTHROPOIETIC DISORDERS 1
Huff, R. L., Elmlinger, P. J., Garcia, J. F., Oda, J. M., Cockrell, M. C., & Lawrence, J. H. (1951) · Journal of Clinical Investigation · doi:10.1172/jci102562 · Cited by 137
Regulation of hepcidin: Insights from biochemical analyses on human serum samples
Kemna, E., Kartikasari, A. E. R., van Tits, L. J. H., Pickkers, P., Tjalsma, H., & Swinkels, D. W. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.10.002 · Cited by 117
Regulation of growth differentiation factor 15 expression by intracellular iron
Lakhal, S., Talbot, N. P., Crosby, A., Stoepker, C., Townsend, A. R. M., Robbins, P. A., Pugh, C. W., Ratcliffe, P. J., & Mole, D. R. (2009) · Blood · doi:10.1182/blood-2008-07-170431 · Cited by 95 · cited 1×
“This hypothesis was strengthened by the recent discovery that iron depletion in vitro induces GDF15 expression, and that infusion of the iron chelator deferoxamine increases plasma GDF15 in humans.(27) In our study, a modest but significant diurnal pattern to GDF15 was observed, with levels increasing slightly during…”
BackgroundRobach, P., Recalcati, S., Girelli, D., Gelfi, C., Aachmann‐Andersen, N. J., Thomsen, J. J., Norgaard, A. M., Alberghini, A., Campostrini, N., Castagna, A., et al. (2009) · Blood · doi:10.1182/blood-2008-09-178095 · Cited by 89
Weizer‐Stern, O., Adamsky, K., Amariglio, N., Levin, C., Koren, A., Breuer, W., Rachmilewitz, E., Breda, L., Rivella, S., Ioav Cabantchik, Z., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06258.x · Cited by 80
Regulation of Transferrin Function and Expression: Review and Update
Lok, C., & Loh, T. T. (1998) · Neurosignals · doi:10.1159/000014542 · Cited by 72
Cazzola, M., Beguin, Y. P., Bergamaschi, G., Guarnone, R., Cerani, P., Barella, S., Cao, A., & Galanello, R. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01600.x · Cited by 58
Krzyżański, W., & Ruixo, J. J. P. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9195-y · Cited by 31
Erythropoietin is both a mitogen and a survival factor
Spivak, J., Pham, T. D., Isaacs, M. A., et al. (1991) · Blood · doi:10.1182/blood.v77.6.1228.bloodjournal7761228 · Cited by 12
Weizer‐Stern, O., Adamsky, K., Amariglio, N., Levin, C., Koren, A., Breuer, W. V., Rachmilewitz, E. A., Gardenghi, S., Rivella, S., Cabantchik, Y., et al. (2006) · Blood · doi:10.1182/blood.v108.11.1556.1556 · Cited by 8
Research works printed but not linked: 4
- Detivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, et al. Hepcidin levels in humans are correlated with hepat- ic iron stores, hemoglobin levels, and hepatic function. Blood. 2005;106(2):746-8.
- Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75(9):976-81.
- Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75(9):976-81.
- Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108(12):3730-5.
Cited by
Sorted by citations
Identification of erythroferrone as an erythroid regulator of iron metabolism
Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., & Ganz, T. (2014) · Nature Genetics · doi:10.1038/ng.2996 · Cited by 1,127
Regulation of erythropoiesis by hypoxia-inducible factors
Haase, V. H. (2013) · Blood Reviews · doi:10.1016/j.blre.2012.12.003 · Cited by 787
“nificant inverse relationship between serum hepcidin and GDF15 levels, which may relate to the EPO doses administered, study size, complexity of regulation and species-dependent differences.(207,221) In the context of iron-deficiency anemia, Tanno and colleagues found that GDF15 serum levels were not elevated,(222) wh…”
BackgroundDetection, evaluation, and management of iron-restricted erythropoiesis
Goodnough, L. T., Nemeth, E., & Ganz, T. (2010) · Blood · doi:10.1182/blood-2010-05-286260 · Cited by 410
Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis
Liu, Q., Davidoff, O., Niss, K., & Haase, V. H. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63924 · Cited by 328
“…in humans have not yet demonstrated a significant association between suppression of hepcidin levels and serum GDF15 levels following EPO administration (46), which may relate to the EPO doses used, study size, complexity of regulation, and species-dependent differences in hepcidin regulation.”
An overview of molecular basis of iron metabolism regulation and the associated pathologies
Silva, B., & Faustino, P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.03.011 · Cited by 300
“However, it was reported that the administration of erythropoietin to healthy individuals lowered the levels of circulatory hepcidin, while no immediate changes of iron levels were detected [114].”
Background
Metadata
- Authors
- Ashby, D. R., Gale, D. P., Busbridge, M., Murphy, K. G., Duncan, N. D., Cairns, T. D., Taube, D. H., Bloom, S. R., Tam, F. W. K., Chapman, R., Maxwell, P. H., & Choi, P.
- Affiliations
- Hammersmith Hospital (GB)
- University College London (GB)
- Imperial College London (GB)
- Venue
- Haematologica
- Published
- 2009-10-14
- Volume
- 95
- Issue
- 3
- Pages
- 505-508
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- PMC
- PMC2833083
- OpenAlex
- W2034565548
- Cited by
- 191
- References
- 26
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 9 · 2023: 7 · 2022: 8 · 2021: 6 · 2020: 8 · 2019: 10 · 2018: 8 · 2017: 14 · 2016: 11 · 2015: 16 · 2014: 21 · 2013: 21 · 2012: 16
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Haematologica (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (NF-SI-0507-10315)
- Medical Research Council
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- erythropoietin, hepcidin, iron metabolism, anemia, bone marrow, phlebotomy, soluble transferrin receptor, growth differentiation factor 15, hematocrit
- MeSH terms
- Adult, Bone Marrow, Erythropoietin, Humans, Injections, Subcutaneous, Iron, Male, Receptors, Transferrin, Transferrin, Antimicrobial Cationic Peptides, Growth Differentiation Factor 15, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
